Apoptosis in normal and neoplastic hematopoiesis

Critical Reviews in Oncology/Hematology

Volumn 24, Issue 3, 1996, Pages 185-211

  Yoshida, Yataro ^a   Anzai, Naoyuki ^a   Kawabata, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; REVIEW;

EID: 0030296754     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00222-3     Document Type: Review

References (273)

1. [1] Alles AK, Alley K, Barrett JC et al. Apoptosis: a general comment. FASEB J 5:2127-2128, 1991.
2. [2] Arends MJ, Wyllie AH. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 32:223-254, 1991.
3. [3] Wyllie AH. Apoptosis. Br J Cancer 67:205-208, 1993.
4. [4] Cotter TG, Lennon VS, Glynn JG, Martin SJ. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res 10:1153-1160, 1990.
5. [5] Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 76:777-779, 1994.
6. [6] Bowen ID. Apoptosis or programmed cell death? Cell Biol Int 17:365-380, 1993.
7. [7] Schwartz LM, Osborne BA. Programmed cell death, apoptosis and killer genes. Immunol Today 14:582-590, 1993.
8. [8] Allen PD, Bustin SA, Newland AC. The role of apoptosis: (programmed cell death) in haemopoiesis and the immune system. Blood Rev 7:63-73, 1993.
9. [9] Fesus L, Davies PJA, Piacentini M. Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol 56:170-177, 1991.
10. [10] Martin SJ, Green DGR. Apoptosis and cancer: the failure of control on cell death and cell survival. Crit Rev Oncol/Hematol 18:137-153, 1995.
11. [11] Dive C, Gregory CD, Phipps DJ et al. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim Biophys Acta 1133:275-285, 1992.
12. [12] Compton MM. Development of an apoptosis endonuclease assay. DNA Cell Biol 10:133-141, 1991.
13. [13] Gorczyca W, Gong J, Darzynkiewicz D. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assay. Cancer Res 53:1945-1951, 1993.
14. [14] Garvy BA, Telford WG, King LE et al. Glucocorticoids and irradiation-induced murine bone marrow B-lineage lymphocytes as determined by flow cytometry. Immunol 79:270-277, 1993.
15. [15] Sun XM, Snowden RT, Skilleter DN et al. A flow-cytometric method for the separation and quantitation of normal and apoptotic thymocytes. Ann Biochem 204:351-356, 1992.
16. [16] Ansari B, Coates PJ, Greenstein BD et al. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170:1-8, 1993.
17. [17] Wijsman JH, Jonker RR, Keijzer JR et al. A new method to detect apoptosis in paraffin sections: In situ end-labeling of fragmented DNA. J Histochem Cytochem 41:7-12, 1993.
18. [18] Gorczyca W, Bigman K, Mittelman A et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemia. Leukemia 7:659-670, 1993.
19. [19] Huang P, Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem 207:163-167, 1992.
20. [20] Tilly JL, Hsueh AJW. Microscale autoradiographic method for the qualitative and quantitative analysis of apoptotic DNA fragmentation. J Cell Physiol 154:519-526, 1993.
21. [21] Martin SJ, Cotter TG. Disruption of microtubules induces an endogenous suicide pathway in human leukaemia HL-60 cells. Cell Tissue Kinet 23:545-559, 1990.
22. [22] Martin SJ, Cotter TG. Ultraviolet B irradiation of human leukaemia HL-60 cell cells in vitro induces apoptosis. Int J Radiat Biol 59:1001-1016, 1991.
23. [23] Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Proliferation 24:203-214, 1991.
24. [24] Zwelling LA, Altschuler E, Cherif A et al. N-(5,5-diacetoxypentoyl)doxorubicine: A novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells. Cancer Res 51:6704-6707, 1991.
25. [25] Kyprianou N, Alexander RB, Isaacs JT: Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst 83:346-350, 1991.
26. [26] Cotter TG, Glynn JM, Echeverr F et al. The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. Anticancer Res 12:773-779, 1992.
27. [27] Hotz MA, Traganos F, Darzynkiewicz Z. Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in Molt-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation. Exp Cell Res 201:184-191, 1992.
28. [28] Gunji HS, Kharbanda S, Kufe D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res 51:741-743, 1991.
29. [29] Martin DJ, Lennon SV, Bonham AM et al. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 145:1859-1867, 1990.
30. [30] O'Connor PM, Wasserman K, Sarang M et al. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 51:6550-6557, 1991.
31. [31] Forbes IJ, Zalewski PD, Giannakis C et al. Induction of apoptosis in chronic lymphocytic leukemia cell and its prevention by phorbol ester. Exp Cell Res 198:367-372, 1992.
32. [32] Cotter TG, Lennon SV, Glynn JG et al. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res 10:1153-1160, 1990.
33. [33] Kolber MA, Broschat KO, Landa-Gonzalez, B. Cytochalasin B induces cellular DNA fragmentation. FASEB J 4:3021-3027, 1990.
34. [34] Cotter TG, Lennon SV, Glynn JG et al. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis. Cancer Res 52:997-1005, 1992.
35. [35] Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 79:448-453, 1990.
36. [36] Wyllie AH, Morris RG. Hormone-induced cell death: Purification and properties of thymocytes undergoing apoptosis after glucocorticoid treatment. Am J Pathol 109:78-87, 1982.
37. [37] Yamada H, Ohyama H. Separation of the dead cell fraction from X-irradiated rat thymocyte suspensions by density gradient centrifugation. Int J Radiat Res 37:695-699, 1980.
38. 2+ -permeable transmembrane channels: pore formation causes extensive DNA degradation and cell lysis. J Exp Med 169:765-777, 1989.
39. [39] McConkey DJ, Aguilar-Santelises M, Hartzel P et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia. J Immunol 146:1072-1076, 1991.
40. [40] McConkey DJ, Orrenius S, Jondal M. Cellular signaling in programmed cell death (apoptosis). Immunol Today 11:120-121, 1990.
41. [41] Cohen JJ, Duke RC. Glucocorticoid activation of a calcium dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol 132:38-42, 1984.
42. [42] McConkey DJ, Hartzel P, Nicotera P et al. Calcium activated DNA fragmentation kills immature thymocytes. FASEB J 3:1843-1849, 1989.
43. 2+ are not required to trigger apoptosis in human leukaemia cells. Clin Exp Immunol 87:465-471, 1992.
44. [44] Rodriguez-Tarduchy G, Colins GM, Lopez-Rivas A. Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J 9:2997-3002, 1990.
45. [45] Buffy G, Miyashita T, Williamson JR et al. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartioning of intracellular calcium and is blocked by enforced bcl-2 oncoprotein production. J Biol Chem 268:6511-6519, 1993.
46. [46] Whyte ML, Meagher L, Haslet C. Elevation of cytosolic calcium delays neutrophil apoptosis (programmed cell death) in vitro. In Proceedings of the 21st Annual FEBS Meeting, Dublin, Ireland, Abs. Fr-78, 1992.
47. ++ in apoptosis in human tumour cell lines. Biochem Soc Trans 20:78S, 1991.
48. [48] Nieto MA, Lopez-Rivas A. IL-2 protects T lymphocytes from glucocorticoid-induced DNA fragmentation and cell death. J Immunol 143:4166-4170, 1989.
49. [49] Zalewski PD, Forbes IJ, Giannakis C. Physiological role for zinc in prevention of apoptosis (gene-directed death). Biochem Int 24:1093-1099, 1991.
50. [50] Treves S, Trentini PL, Ascanelli M et al. Apoptosis is dependent on intracellular zinc and independent of intracellular calcium in lymphocytes. Exp Cell Res 211:339-343, 1994.
51. [51] Martin SJ, Mazdai G, Strain JJ et al. Programmed cell death (apoptosis) in lymphoid and myeloid cell lines during zinc deficiency. Clin Exp Immunol 83:338-343, 1991.
52. [52] Mccabe MJ, Jiang SA, Orrenius S. Chelation of intracellular zinc triggers apoptosis in mature thymocytes. Lab Invest 69:101-110, 1993.
53. [53] Wyllie AH, Morris RG, Smith AL et al. Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142:67-77, 1984.
54. [54] Kizaki H, Tadakuma T, Okada C et al. Activation of a suicide process of thymocytes through DNA fragmentation by calcium ionophores and phorbol esters. J Immunol 143:1790-1794, 1989.
55. [55] Sellins KS, Cohen JJ. Gene induction by γ-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 139:3199-3206, 1987.
56. [56] Cohen JJ, Duke RC, Chervenak R et al. DNA fragmentation in targets of CTL: An example of programmed cell death in the immune system. Adv Exp Med Biol 184:493-508, 1985.
57. [57] Shi Y, Szalay MG, Paskar M et al. Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation. J Immunol 144:3326-3333, 1990.
58. [58] Kizaki H, Shimada H, Ohsaka F et al. Adenosine, deoxyadenosine, and deoxyguanosine induce DNA cleavage in mouse thymocytes. J Immunol 141:1652-1657, 1988.
59. 2+ mediated endonuclease activation. Science 242:256-259, 1988.
60. [60] Nieto MA, Gonzalez A, Garbon F et al. Apoptosis in human thymocytes after treatment with glucocorticoids. Clin Exp Immunol 88:341-344, 1992.
61. [61] Waring P. DNA fragmentation induced in macrophages by gliotoxin does not require protein synthesis and is preceded by raised inositol triphosphate levels. J Biol Chem 265:14476-11480, 1990.
62. [62] Collins RJ, Harmon BV, Souvlis T et al. Effects of cycloheximide on B-chronic lymphocytic leukaemic and normal lymphocytes in vitro. Induction of apoptosis. Br J Cancer 64:518-522, 1991.
63. [63] Martin SV. Protection of RNA synthesis inhibition induces apoptosis of mature human CD4+ T cell blasts. Immunol Letts 35:125-134, 1993.
64. [64] Baxster GD, Smith PJ, Lavin MF. Molecular changes associated with induction of cell death in a human T-cell leukaemia line: putative nucleases identified as histones. Biochem Biophys Res Commun 162:30-37, 1989.
65. [65] Duke RC, Chervenak R, Cohen JJ. Endogenous endonuclease-induced DNA fragmentation: An early event in cell-mediated cytolysis. Proc Natl Acad Sci USA 80:6361-6365, 1983.
66. [66] Anzai N, Kawabata H, Hirama T et al. Marked apoptosis of human myelomonocytic leukemia cell line P39. Significance of cellular differentiation. Leukemia 8:446-453, 1994.
67. [67] Takano YS, Harmon BV, Kerr JFR. Apoptosis induced by mild hyperthermia in human and murine tumour cell line: A study using electron microscopy and DNA gel electrophoresis. J Pathol 163:329-336, 1991.
68. [68] Agarwal ML, Clay ME, Harvey EJ et al. Photodynamic therapy induces rapid cell death by apoptosis in 15178Y mouse lymphoma cells. Cancer Res 51:5993-5996, 1991.
69. [69] Baxter GD, Collins RJ, Harmon BV et al. Cell death in acute leukemia. J Pathol 158:123-129, 1989.
70. [70] Martin SJ. Apoptosis: Suicide, execution, or murder? Trends Cell Biol 3:141-144, 1993.
71. [71] Odaka C, Kizaki H, Tadakuma T. T cell receptor-mediated DNA fragmentation and cell death in T cell hybridomas. J Immunol 144:2096-2101, 1990.
72. [72] Ojeda F, Guarda MI, Maldonado C et al. Protein kinase-C involvement in thymocyte apoptosis induced by hydrocortisone. Cell Immunol 125:535-539, 1990.
73. [73] Shinkovics J, Horvath J. Apoptosis by genetic engineering. Leukemia 8:98-102, 1994.
74. [74] McConkey DJ, Hartzell P, Perez JF et al. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor. J Immunol 143:1801-1806, 1989.
75. [75] Macfarlane DE, O'Donnell PS. Phorbol ester induces apoptosis in HL-60 promyelocytic cells but not in HL-60 PET mutant. Leukemia 7:1846-1851, 1993.
76. [76] Jarvis ED, Turner AJ, Povirk LF et al. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54:1707-1714, 1994.
77. [77] Evans VG. Multiple pathways to apoptosis. Cell Biol Int 17:461-476, 1993.
78. [78] Owens GP, Cohen JT. Identification of genes involved in programmed cell death. Cancer Metast Rev 11:149-156, 1992.
79. [79] McConkey DJ, Jondal M, Orrenius S. Cellular signaling in thymocyte apoptosis. Sem Immunol 4:371-377, 1992.
80. [80] McConkey DJ, Orrenius S, Okret S et al. Cyclic AMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes. FASEB J 7:580-585, 1993.
81. [81] Otani H, Erdos M, Keonard WJ. Tyrosine kinase(s) regulates apoptosis and bcl-2 expression in a growth factor-dependent cell line. J Biol Chem 268:22733-22736, 1993.
82. [82] Waddick KG, Park Chae H, Tuel-Ahlgren L et al. Engagement of CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis. Radiat Res 136:313-319, 1993.
83. [83] Sarin A, Adams DH, Henkart PA. Protease inhibitors selectively block T-cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells. J Exp Med 178:1673-1700, 1993.
84. [84] Obeid LM, Linardic CM, Karolak LA et al. Programmed cell death induced by ceramide. Science 259:1769-1771, 1993.
85. [85] Hanuum YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269:3125-3128, 1994.
86. [86] Jarvis WD, Kolesnick RN, Fornari FA et al. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 91:73-77, 1994.
87. [87] Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77:325-328, 1994.
88. [88] Peitsch MC, Manherz HG, Tschopp J. The apoptosis endonucleases: cleaning up after cell death? Trends Cell Biol 4:37-41, 1994.
89. [89] Wyllie AH, Arends MJ, Morris RG et al. The apoptosis endonuclease and its regulation. Sem Immunol 4:389-397, 1992.
90. [90] Peitsch MC, Polzar B, Stephan H et al. Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). EMBO J 12:371-377, 1993.
91. [91] Peitsch MC, Muller C, Tschopp J. DNA fragmentation during apoptosis is caused by frequent single-strand cuts. Nucleic Acids Res 21:4206-4209, 1993.
92. [92] Barry MA, Eastman A. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Arch Biochem Biophys 300:440-450, 1993.
93. [93] Barry MA, Reynolds JE, Eastman A. Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res 53:2349-2357, 1993.
94. [94] Fernandes RS, Cotter TG. Activation of a calcium magnesium independent endonuclease in human leukemic cell apoptosis. Anticancer Res 13:1253-1260, 1993.
95. 2+ -dependent endonuclease activity in myeloid leukemia cell nuclei capable of producing internucleosomal DNA cleavage. Biochem Biophys Res Commun 191:247-254, 1993.
96. [96] Schwartz LM, Osborne. Programmed cell death, apoptosis and killer genes. Immunol Today 14:582-590, 1993.
97. [97] Brown DG, Sun X-M, Cohen GM. Dexamethazone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J Biol Chem 268:3037-3039, 1993.
98. [98] Oberhammer F, Wilson JW, Dive C et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12:3679-3684, 1993.
99. [99] Askew DS, Ashmun RA, Simmons BC et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922, 1991.
100. [100] Askew DS, Ihle J, Cleveland JL. Activation of apoptosis associated with enforced myc expression in myeloid progenitor cells is dominant to the suppression of apoptosis by interleukin-3 or erythropoietin. Blood 82:2079-2087, 1993.
101. [101] Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128, 1992.
102. [102] Wyllie AH, Rose KA, Morris RG et al. Rodent fibroblast tumours expressing human myc and ras gene: growth, metastasis and endogenous oncogene expression. Br J Cancer 56:251-259, 1987.
103. [103] Neiman PE, Thomas SJ, Loring G. Induction of apoptosis during normal and neoplastic B-cell development in the Bursa of Fabricius. Proc Natl Acad Sci USA 88:5857-5861, 1991.
104. [104] Kyprianou N, English HF, Davidson NE et al. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162-166, 1991.
105. [105] Pallavicini MG, Rosette C, Reitsma M et al. Relationship of the c-myc gene copy number and gene expression: Cellular effects of elevated c-myc protein. J Cell Physiol 143:372-380, 1990.
106. [106] Milner AE, Grand RJD, Waters CM et al. Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene 8:3385-3391, 1993.
107. [107] Shi Y, Glynn JM, Guilbert LJ et al. Role for c-myc in activation-induced apoptotic cell death in T-cell hybridomas. Science 257:212-214, 1992.
108. [108] Yuh YS, Thompson EB. Glucocorticoid effect on oncogene/ growth gene expression in human T lymphocyte leukemic cell line CCRF-CEM. J Biol Chem 264:10904-10910, 1989.
109. [109] Bissonnette RP, Shi Y, Mahboudi A et al. C-myc and apoptosis. In: Tomei LD, Cope FO eds. Apoptosis II. The Molecular Basis of Apoptosis in Diseases. New York: Cold Spring Harbor Laboratory Press, 1994; 327-356.
110. [110] Blackwell TK, Krezner L, Blackwood EM et al. Sequence specific DNA binding by the c-MYC protein. Science 250:1149-1151, 1990.
111. [111] Prendergast GC, Lawe D, Ziff, EB. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and Ras cotransformation. Cell 65:395-407, 1991.
112. [112] Amati B, Littlewood TD, Evan GI et al. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 12:5083-5087, 1993.
113. [113] Rustgi AK, Dyson N, Bernards R. Amino-terminal domains of c-myc and n-myc proteins mediate binding to the retinoblastoma gene product. Nature 352:541-544,1991.
114. [114] Goodrich DW, Lee W-H. Abrogation by c-myc of G1 phase arrest induced by RB protein but not by p53. Nature 360:177-179, 1992.
115. H on chromosome 14 and near a transcriptional unit on 18. Cell 41:899-906, 1985.
116. [116] Tsujimoto Y, Croce C. Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214-5218, 1986.
117. [117] Huary M, Freitas A, Hermitte V et al. The physiology of bcl-2 expression in murine B lymphocytes. Oncogene 8:1257-1262, 1993.
118. [118] Liu Y-J, Joshua DE, Williams GT et al. Mechanisms of antigen-driven selection in germinal centres. Nature 342:929-931, 1989.
119. [119] Campana D, Coustan-Smith E, Manabe A et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 81:1025-1031, 1993.
120. + T lymphocytes in acute infectious mononucleosis supporting their susceptibility to programmed cell death. Blood 82:521-527, 1993.
121. [121] Reed JC, Tsujimoto Y, Alpers JD et al. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science 236:1295-1299, 1987.
122. [122] Miyashita T, Reed JC. Bcl-2 oncogene blocks chemotherapy-induced apoptosis in a human luekemia cell line. Blood 81:151-157, 1993.
123. [123] Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differentiation 4:41-47, 1993.
124. [124] Walton MI, Whysong D, O'Connor PM et al. Constitutive expression of human bcl-2 modulates nitrogen mustard and camtpothecin induced apoptosis. Cancer Res 53:1853-1861, 1993.
125. [125] Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes hemopoietic cell survival and cooperation with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988.
126. [126] Nunez G, Hockenbery D, McDonnel TJ et al. Bcl-2 maintains B cell memory. Nature 353:71-73, 1991.
127. [127] Hockenbery D, Nunez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990.
128. [128] McDonnell TJ, Deane N, Platt FM et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 57:79-88, 1989.
129. [129] Strasser A, Whittigham S, Vaux DL et al. Enforced bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88:8661-8665, 1991.
130. [130] Sentman CL, Shutter JR, Hockenbery D et al. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67:879-888, 1991.
131. [131] Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T-cell death and perturbs thymic self-censorship. Cell 67:889-899, 1991.
132. [132] Siegel RM, Katsumata M, Miyashita T et al. Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc Natl Acad Sci USA 89:7003-7007, 1992.
133. [133] Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogene. Nature 359:554-556, 1992.
134. [134] Bissonnette RP, Echeverri F, Mahboubi A et al. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552-554, 1992.
135. [135] Wagner AJ, Small MB, Hay N. Myc-mediated apoptosis is blocked by ectopic expression of bcl-2. Mol Cell Biol 13:2432-2440, 1993.
136. [136] Hockenbery D, Zutter M, Hickey W et al. Bcl-2 is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965, 1991.
137. [137] Lagasse E, Weissman IL. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med 179:1047-1052, 1994.
138. [138] Vaux DL, Weissman L, Kim SK. Prevention of programmed cell death in Caenorhabdis elegans by human bcl-2 gene. Science 258:1955-1957, 1992.
139. [139] Chen-Levy Z, Nourse J, Clearly ML. The bcl-2 candidate protooncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9:701-710, 1989.
140. [140] Jacobson MD, Burne JF, King MP et al. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361:365-369, 1993.
141. [141] Hockenbery DM, Oltavi ZN, Yin X-M et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251, 1993.
142. [142] Veis DJ, Sorenson CM, Shutter JR et al. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229-240, 1993.
143. [143] Nunez G, London L, Hockenbery D et al. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602-3610, 1990.
144. [144] Strasser A, Harris AW, Bath ML et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333, 1990.
145. [145] McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgeneic for the t(14;18). Nature 349:254-256, 1991.
146. [146] Wang Y, Szekely L, Okan I et al. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427-3431, 1993.
147. [147] Chiou S-K, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14:2556-2563, 1994.
148. [148] Vaux DL, Weissman IL. Neither macromolecular synthesis nor myc is required for cell death via the mechanism that can be controlled by bcl-2. Mol Cell Biol 13:7000-7005, 1993.
149. [149] Delia D, Aliello A, Soligo D et al. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79:1291-1298, 1992.
150. [150] Oltavi Z, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993.
151. [151] Boise LH, Gonzalez-Garcia M, Postema CE et al. Bcl-x, a bcl-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608, 1993.
152. [152] Kozopas KM, Yang T, Buchan HL et al. Mcl-1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci USA 90:3516-3520, 1993.
153. [153] Levine AJ, Momand J. Tumor suppressor genes: The p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1032:119-136, 1990.
154. [154] Yonish-Rouach E, Resnitzky D, Lotem J et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991.
155. [155] Yonish-Rouach E, Grunwald D, Wilder S et al. P53-mediated cell death: Relationship to cell cycle control. Mol Cell Biol 13:1415-1423, 1993.
156. [156] Ryan JJ, Danish R, Gottlieb CA et al. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13:711-719, 1993.
157. [157] Ramqvist T, Magnusson KP, Wang Y et al. Wild-type p53 induced apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8:1495-1500, 1993.
158. [158] Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092-1096, 1993.
159. [159] Lowe S, Schmitt EM, Smith SW et al. P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
160. [160] Clarke AR, Purdie CA, Harrison DJ et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993.
161. [161] Lowe SW, Ruley HE, Jacks T et al. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
162. [162] Lowe SW, Jacks T, Housman DE et al. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 91:2026-2030, 1994.
163. [163] Mcgahon A, Bissonnette R, Schmitt M et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179-1187, 1994.
164. [164] Bedi A, Zehnbauer BA, Barber JP et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038-2044, 1994.
165. [165] Evans CA, Owen-Lynch PJ, Whetton AD et al. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 53:1735-1738, 1993.
166. [166] Laneuville P, Timm M, Hudson AT. Bcr/abl expression in 32D cl3(G) cells inhibited apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res 54:1360-1366, 1994.
167. [167] Smetsersn TFCM, Skorski T, van de Locht LTF et al. Antisense BCR-ABL ologonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Luekemia 8:129-140, 1994.
168. [168] Sawyers CL, Callahan W, Witte ON. Dominant negative myc blocks transformation by abl oncogenes. Cell 70:901-910,1991.
169. [169] Itoh N, Yonehara S, Ishii M et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243, 1991.
170. [170] Trauth BC, Klas C, Peters AMJ et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305, 1989.
171. [171] Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992.
172. [172] Debatin KM, Goldmann C, Bamford R et al. Monoclonal-antibody-mediated apoptosis in adult T-cell leukemia. Lancet 335:497-500, 1990.
173. [173] Debatin KM, Goldmann C, Waldmann TA et al. Apo-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 81:2972-2977, 1993.
174. [174] Mapara MY, Bargou R, Zugck C et al. Apo-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol 23:702-708, 1993.
175. [175] Moller P, Henne C, Leithauser F et al. Coregulation of the Apo-1 antigen with intracellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 81:2067-2075, 1993.
176. [176] Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 151:621-627, 1993.
177. [177] Wong GHW, Goeddel DV. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J Immunol 152:1751-1756, 1994.
178. [178] Rotello RJ, Lieberman RC, Purchio AF et al. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β1 in cultured uterine epithelial cells. Proc Natl Acad Sci USA 88:3412-3415, 1991.
179. [179] Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line by transforming factor β1. Cancer Res 52:385-388, 1992.
180. [180] Stein GH, Beeson M, Gordon L. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science 249:666-669, 1990.
181. [181] Rubin LL, Philpott KL, Brooks SF. The cell cycle and cell death. Current Biol 3:391-394, 1993.
182. [182] Murray AW. Creative blocks: cell cycle checkpoints and feed-back controls. Nature 359:599-604, 1992.
183. [183] Woronicz JD, Calnan B, Ngo V et al. Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. Nature 367:277-281, 1994.
184. [184] Hengartner MO, Ellis RE, Horvitz R. Caenorabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356:494-449, 1992.
185. [185] Bowen ID. Apoptosis or programmed cell death? Cell Biol Int 17:365-380, 1993.
186. [186] Yuan J, Horwitz HR. The Caenorabditis elegans genes ced-3 and ced-4 act autonomously to cause programmed cell death. Dev Biol 138:33-41, 1990.
187. [187] Miura M, Zhu H, Rotello R et al. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75:653-660, 1993.
188. [188] Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817-829, 1986.
189. [189] Ellis HM, Yuan J, Horwitz HR. Mechanism and function of cell death. Annu Rev Cell Biol 7:663-698, 1991.
190. [190] Wyllie AH, Rose RG, Morris CM et al. Rodent fibroblast tumors expressing human myc and ras genes: Growth, metastasis and endogenous oncogene expression. Br J Cancer 56:251-259, 1987.
191. [191] Moore J, Boswell S, Hoffman R et al. Mutant H-ras over-expression inhibits a random apoptotic nuclease in myeloid leukemia cells. Leukemia Res 17:703-709, 1993.
192. [192] Rapp UR, Troppmair G, Carroll M et al. Role of raf-1 protein kinase in IL-3 and GM-CSF-mediated signal transduction. Curr Top Microbiol Immunol 166:129-139, 1990.
193. [193] Cook WD, Metcalf D, Nicola NA et al. Malignant transformation of growth factor dependent-myeloid cell line by Abelson virus without evidence of an autocrine mechanism. Cell 41:677-683, 1985.
194. [194] Cleveland JL, Dean M, Wang JY et al. Abrogation of IL-3 dependence of myeloid FDCP-1 cells by tyrosine kinase oncogenes is associated with induction of c-myc. Curr Top Microbiol Immunol 141:300-309, 1988.
195. [195] Newman SL, Henson JE, Henson PM. Phagocytosis of senescent neutrophils by human monocytes derived macrophages and rabbit inflammatory macrophages. J Exp Med 156:430-442, 1982.
196. [196] Savill JS, Wyllie AH, Henson JE et al. Macrophages phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 83:865-875, 1989.
197. [197] Whyte MKB, Meagher LC, MacDermot J et al. Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 150:5124-5134, 1993.
198. [198] Brach MA, deVos S, Gruss H-J et al. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 80:2920-2924, 1992.
199. [199] Colotta F, Re F, Polentarutti N et al. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80:2012-2020, 1992.
200. [200] Pericle F, Liu JH, Diaz JI et al. Interleukin-2 prevention of apoptosis in human neutrophils. Eur J Immunol 24:440-444, 1994.
201. [201] Whyte MKB, Hardwick SJ, Meagher LC et al. Transient elevations of cytosolic free calcium retard subsequent apoptosis in neutrophils in vitro. J Clin Invest 92:446-455, 1993.
202. [202] Lee A, Young SK, Henson PM et al. Modulation of neutrophil programmed cell death by inflammatory mediators. FASEB J 3:A1344, 1989.
203. [203] Lagasse E, Weisman IL. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med 179:1047-1052, 1994.
204. [204] Mangan DF, Robertson B, Wahl SM. IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes. J Immunol 148:1812-1816, 1992.
205. [205] Wright SC, Kumar P, Tam AW et al. Apoptosis and DNA fragmentation precede TNF induced cytolysis in U937 cells. J Cell Biochem 48:344-355, 1992.
206. [206] Savill JS, Henson PM, Haslett C. Phagocytosis of aged human neutrophils by macrophages is mediated by a novel 'charge sensitive' recognition mechanism. J Clin Invest 84:1518-1527, 1989.
207. [207] Savill J, Hogg N, Ren Y et al. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90:1513-1522, 1992.
208. [208] Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol 1:335-359, 1983.
209. [209] Stern M, Meagher L, Savill J et al. Apoptosis in human eosinophils leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 148:3543-3549, 1992.
210. [210] Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of hemopoietic stem cells in vitro. J Cell Physiol 91:335-344, 1977.
211. [211] Manabe A, Coustan-Smith E, Behm F et al. Bone marrow-derived stromal cells prevents apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 79:2370-2377, 1992.
212. [212] Meredith JE, Fazeli B Jr., Schwarz MA. The extracellular matrix as a surviving factor. Mol Biol Cell 4:953-961, 1993.
213. [213] Raff MC. Social controls on cell survival and cell death. Nature 356:397-400, 1992.
214. [214] Kelly LL, Koury MJ, Bondurant MC. Regulation of programmed cell death in erythroid progenitor cells by erythropoietin: Effects of calcium and of protein and RNA syntheses. J Cell Physiol 151:487-496, 1992.
215. [215] Yu H, Bauer B, Lipke GL et al. Apoptosis and hematopoiesis in murine fetal liver. Blood 81:373-384, 1993.
216. [216] Muta K, Krantz S. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor 1 as well as by erythropoietin. J Cell Physiol 156:264-271, 1993.
217. [217] Nakamura Y, Komatsu N, Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science 248:378-381, 1990.
218. [218] Perdahl EB, Naprstek BL, Wallace WC et al. Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood 83:645-650, 1994.
219. [219] Morey AL, Perguson DJP, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: Evidence of cell death by apoptosis. J Pathol 169:213-220, 1993.
220. [220] Yuan J, Angelucci E, Lucarelli G et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe β-thalassemia (Cooley's anemia). Blood 82:374-377, 1993.
221. [221] Mangan DF, Wahl SM. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol 147:3408-3412,1991.
222. [222] Fernandez-Ruiz E, Rebollo A, Nieto MA et al. IL-2 protects T-cell hybrids from the cytotoxic effect of glucocorticoids. J Immunol 143:4146-4151,1989.
223. [223] Duke RC, Cohen JJ. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res 5:289-299, 1986.
224. [224] Huang R-W, Tsuda H, Takatsuki K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells. Int J Hematol 58:83-92, 1993.
225. [225] Tsuda H, Huang R-W, Takatsuki K. Interleukin-2 prevents programmed cell death in adult T-cell leukemia cells. Jpn J Cancer Res 84:431-437, 1993.
226. [226] Collins MKL, Marvel J, Malde P et al. Interleukin-3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 176:1043-1051, 1992.
227. [227] Mekori YA, Oh CK, Metcalfe DD. IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. J Immunol 151:3775-3784, 1993.
228. [228] Iemura A, Tsai M, Ando A et al. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 144:321-328, 1994.
229. [229] Caeceres-Cortes J, Rajotte D, Dumouchel J et al. Product of the steel factor suppresses apoptosis in hemopoietic cells. Comparison with pathways activated by granulocyte macrophage colony-stimulating factor. J Biol Chem 269:12084-12091, 1994.
230. [230] Lotem J, Crajor EG Jr, Sachs L. Rescue from programmed cell death in leukemic and normal myelolid cells. Blood 78:953-960, 1991.
231. [231] Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells. Science 248:378-381, 1990.
232. [232] Williams GT, Smith CA, Spooncer E et al. Hemopoietic colony-stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76-79, 1990.
233. [233] Her E, Frazer J, Austen F et al. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. J Clin Invest 88:1982-1987, 1991.
234. [234] Taga K, Cherny B, Tosato G. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 5:1599-1608, 1993.
235. [235] Panaiotidis P, Ganeshaguru K, Jabbar SAB et al. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 85:439-445, 1993.
236. [236] Danescu M, Rubio-Trujillo M, Biron G et al. Interleukin-4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates bcl-2 expression. J Exp Med 176:1319-1326, 1992.
237. [237] Williams GT. Programmed cell death: Apoptosis and oncogenesis. Cell 65:1097-1098, 1991.
238. [238] Koury MJ. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol 20:391-394, 1992.
239. [239] Taetle R, Payne C, Santos BD et al. Effects of transforming growth factor β1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res 53:3386-3393, 1993.
240. [240] Alam R, Forsythe P, Stafford S et al. Transforming growth factor β abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 179:1041-1045, 1994.
241. [241] Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80:1750-1757, 1992.
242. [242] Oritani K, Kaisho T, Nakajima K et al. Retinoic acid inhibits interleukin-6-induced macrophage differentiation and apoptosis in a murine hematopoietic cell line, Y6. Blood 80:2298-2305, 1992.
243. [243] Mangan DF, Robertson B, Wahl SM. IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes. J Immunol 148:1812-1816, 1992.
244. [244] Manabe A, Coustan-Smith E, Kumagai M et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high risk acute lymphoblastic leukemia. Blood 83:1731-1737, 1994.
245. [245] Bullock G, Tang C, Tourkina E et al. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol 21:1640-1647, 1993.
246. [246] Bhalla K, Tang C, Ibrado AM et al. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (PIXY 321) enhances high dose AraC-induced programmed cell death or apoptosis in human myeloid leukemia cells. Blood 80:2883-2890, 1992.
247. [247] Bessho M, Yoshida S, Sakate K et al. Suppression of the development of murine myeloid leukemia with granulocyte colony-stimulating factor by inducing apoptosis of leukemic cells. Leukemia 8:1185-1190, 1994.
248. [248] Huang Y, Waxman S. Enhanced apoptosis in leukemia cells following treatment with combination fluropyrimidines and differentiation inducers. Mol Cell Differentiation 2:83-100, 1994.
249. 1 arrest. J Clin Invest 89:954-960, 1992.
250. [250] Selvakumaran M, Reed JC, Liebermann D et al. Progression of the myeloid differentiation program is dominant to transforming growth factor-β1-induced apoptosis in M1 myeloid leukemia cells. Blood 84:1036-1042, 1994.
251. [251] Naumofsky L, Cleary ML. Bcl 2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. Blood 83:2261-2267, 1994.
252. [252] Park JR, Robertson K, Hickstein DD et al. Dysregulated bcl-2 expression inhibits apoptosis but not differentiation of retinoic acid-induced HL-60 granulocytes. Blood 84:440-445, 1994.
253. [253] Fairbairn LJ, Cowling GJ, Reipert BM et al. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell 74:823-832, 1993.
254. [254] Afford SC, Pongracz J, Stockley RA et al. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U937 and human neutrophils. J Biol Chem 267:21612-21616, 1992.
255. [255] Solary E, Bertrand R, Kohn KW et al. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81:1359-1368, 1993.
256. [256] Delia D, Aiello A, Lombardi L et al. N-(4-hydroxyphenol)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53:6036-6041, 1993.
257. [257] Yoshida Y. Hypothesis: apoptosis may be responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 7:144-146, 1993.
258. [258] Ohmori M, Ohmori S, Ueda Y et al. Ineffective hematopoiesis in the myelodysplastic syndrome (MDS) as studied by daily in situ observation of colony-cluster formation. Int J Cell Cloning 9:521-530, 1991.
259. [259] Raza A, Mundel S, Shetty V et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 63:265-278, 1996.
260. [260] Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leukemia Lymphoma 2:415-418, 1990.
261. [261] Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 82:15-21, 1993.
262. [262] Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542, 1994.
263. [263] Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematopoietic cell lineages. Blood 84:2391-2411, 1994.
264. [264] Sugimoto K, Hirano N, Toyoshima H et al. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 81:3022-3026, 1993.
265. [265] Walker NI, Harmon BV, Gobe GC et al. Patterns of cell death. Methods Arch Exp Pathol 13:18-54, 1988.
266. [266] Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013-2026, 1994.
267. [267] Kerr JFR, Searle J. A suggested explanation for the paradoxically slow rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 107:41-44, 1972.
268. [268] Leoncini L, Del Vecchio MT, Megha P et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 142:755-763, 1993.
269. [269] Johnson PWM, Watt SM, Betts DR et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 82:1848-1857, 1993.
270. [270] Imamura J, Miyoshi I, Koeffler HP. P53 in hematologic malignancies. Blood 54:2412-2421, 1994.
271. [271] Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 341:1251-1254, 1993.
272. [272] Williams GT. Programmed cell death: Apoptosis and oncogenesis. Cell 65:1097-1098, 1991.
273. [273] Dive C, Hickman JA. Drug-target interactions: Only the first step in a commitment to a programmed cell death? Br J Cancer 64:192-194, 1991.